imm2510
Recombinant proteinexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 18, 2021 (NCT05972460)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170787 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2025 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT06746870 | Phase 2 | Dec 31, 2024 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT06764836 | Phase 1 | Jul 23, 2024 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT05972460 | Phase 1 | Aug 18, 2021 | Chinese Academy of Medical Sciences, Fudan University, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | For profit | 4 | 4 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1